Chapter Eighteen - Meningeal Afferent Signaling and the Pathophysiology of Migraine
Introduction
Migraine is a subtype of headache characterized by repetitive episodes of intense unilateral throbbing head pain lasting many hours to days. However, it is a multiphasic disorder that comprises complex symptomology that can vary greatly among patients. These complex features of migraine differentiate it from other types of chronic pain and include the presence of premonitory symptoms, an aura, and during the headache phase, severe nausea, vomiting, and hypersensitivity to light and sound. Although migraine is episodic in nature, together these collections of symptoms cause an entire attack to last close to a week, and given the severity, migraine has a significant negative impact on a patient's quality of life. The World Health Organization's Global Burden of Disease Study conducted in 2010 found migraine headache to be the third most prevalent disease across the globe, preceded only by dental caries and tension type headache.1 Given the current understanding of migraine as a pathological condition of the nervous system, migraine is thus the most common neurological disorder with an estimated 33% of women and 10% of men affected by the condition.1, 2, 3 Despite the prevalence, the basic physiology and underlying contributing factors to the development of migraine headache is still poorly understood.
Section snippets
Features of Migraine
Migraines comprise four phases: premonitory phase (also commonly referred to as the prodrome), aura, headache, and postdrome2, 3 (Fig. 1). Studies have estimated that the number of patients with migraine who experience premonitory symptoms may range from as low as 37% to as high as 80%.4, 5 The premonitory phase occurs hours to days before the actual headache and can be a reliable predictor of an upcoming migraine for some patients.4 This phase consists of symptoms that range in severity such
Current Migraine Treatments
Migraine is an extremely disabling disorder,1 a fact made more troubling by the lack of efficacy of currently available therapeutics. Treatment typically falls in one of the two categories, abortive and prophylactic. Abortive agents are taken at the onset of headache or during aura with the goal being termination or at least a decrease in intensity of the building attack. Prophylactic therapies are given daily to patients who have frequent migraines (e.g., > 5 per month) with the goal of
Anatomy of the Meningeal Afferent System
The meninges are innervated predominantly by afferents whose cell bodies reside in the trigeminal ganglion (Fig. 2). The trigeminal nerve is the fifth cranial nerve that exits the brainstem at the level of the pons as a single nerve root, passes through the trigeminal ganglion, and continues distally from the ganglion as separate nerve branches.28, 29 There are three major branches that emerge from the ganglion into V1, V2, and V3 subdivisions. Each branch innervates a distinct dermatome. The
Migraine Pathophysiology
Although the brain lacks sensory innervation, which renders it incapable of sensing noxious stimuli, studies dating as far back as 1940 have shown that sensory afferents that innervate the cranial meninges, particularly the dura mater, are in fact mechanically (and chemically) sensitive.32, 33, 34, 35, 36, 37, 38 The earliest of these studies showed that in response to stimulation of the meninges, conscious humans report pain and no other sensation, indicating that the meninges are innervated
Potential Mechanisms of Dural Afferent Activation
Dural afferents are capable of sensing noxious stimuli generated within the dura and the pain that arises during migraine is likely to involve the activation of these primary afferent nociceptors.55, 56 However, the events that lead to the activation and/or sensitization of these neurons are not fully known.8, 57, 58 The dura is often overlooked as just one of the three meningeal layers; however, the dura mater regulates events in the overlying skull during development. Ultimately, the dura
Ion Channels and Dural Afferent Activation
Acid-sensing ion channels or ASICs are a family of four ion channels consisting of, ASIC1–ASIC4, with several splice variants.75, 76, 77 ASIC1–3 are sensitive to various ranges of pH from approximately 4.5 to just above 7.0. ASIC4 is not a pH-sensitive channel. Although ASICs are abundant throughout the nervous system, including expression primary sensory neurons, ASIC3 is largely restricted to the periphery.77, 78 ASICs on dural afferents may act as an indicator of changes in extracellular pH.
Dural Afferent Input May Lead to Neuroplasticity
Although the events that actually initiate a migraine attack remain unknown, the ultimate activation of the trigeminovascular system is considered to be essential147, 148. Trigeminovascular activation may provoke release of multiple excitatory neurotransmitters including substance P, neurokinin A, and CGRP from dural afferent terminals resulting in neurogenic vasodilation of dural blood vessels, release of proinflammatory mediators, degranulation of mast cells, and plasma protein extravasation.9
Neuroplasticity and Migraine
As discussed above, there are a number of proposed mechanisms that may contribute to the pathophysiology of migraine, one of which involves “neuroplasticity” in the peripheral and central nervous systems. There are two different kinds of neuroplasticity, one that is beneficial, contributing processes within the brain that lead to learning and memory, and one that is harmful, contributing to pathological pain or migraine. The underlying mechanisms mediating these forms of plasticity are thought
CGRP and Migraine Plasticity
Numerous studies show that CGRP plays a critical role in migraine headache. CGRP is a neuropeptide produced by peripheral neurons commonly affiliated with nociceptive signals entering the spinal cord due to its release from C-fibers at this site.32, 34, 36 The role of CGRP in migraine is still evolving, but many advances have been made recently. As described above, it was previously hypothesized that the cause of migraine pain was due to vasodilation of blood vessels innervating the cerebrum39,
BDNF and Migraine
Long-term potentiation (LTP) is an example of neuroplasticity, where the persistent activation of a synapse leads to long-lasting changes in transmission between two neurons. While LTP has long been implicated in learning and the formation of memories at central synapses in the cortex and hippocampus, LTP can play an important role in the dorsal horn of the spinal cord leading to pain plasticity.91 LTP is separated into two phases: an early and late or maintenance phase. While early-phase LTP
Conclusion
Migraine is the most common neurological disorder and is one of the most disabling disorders worldwide. Surprisingly, the pathophysiological mechanisms contributing to this prevalent disorder remain poorly understood. One primary result of the poor understanding of the condition is slow development of novel therapeutics. The gold standard in the treatment of migraine, triptans, was developed on an outdated hypothesis for the mechanism contributing to migraine, vasodilation. Although they have
Acknowledgments
This work was supported by funding from the National Institutes of Health (NS072204) and the Migraine Research Foundation.
References (163)
- et al.
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Lancet
(2012) - et al.
Neurobiology of migraine
Neuroscience
(2009) - et al.
Is stress a trigger factor for migraine?
Psychoneuroendocrinology
(2007) - et al.
Behavioral management of the triggers of recurrent headache: a randomized controlled trial
Behav Res Ther
(2014) The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache
Pharmacol Ther
(2008)- et al.
New drugs in migraine treatment and prophylaxis: telcagepant and topiramate
Lancet
(2010) - et al.
Clinical features, pathophysiology, and treatment of medication-overuse headache
Lancet Neurol
(2010) - et al.
The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis
Value Health
(2009) - et al.
Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors
Neurosci Biobehav Rev
(1997) - et al.
Expression of calcitonin gene-related peptide in anterior and posterior horns of the spinal cord after brachial plexus injury
J Clin Neurosci
(2010)
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs
Pharmacol Ther
What has functional neuroimaging done for primary headache … and for the clinical neurologist?
J Clin Neurosci
Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides
Neuropeptides
The sensory innervation of the calvarial periosteum is nociceptive and contributes to headache-like behavior
Pain
Dural fibroblasts play a potential role in headache pathophysiology
Pain
Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo
Brain Res
Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin
Neuron
Acid-sensing ion channels (ASICs): pharmacology and implication in pain
Pharmacol Ther
Response properties of trigeminal brain stem neurons with input from dura mater encephali in the rat
Neuroscience
ATP can enhance the proton-induced CGRP release through P2Y receptors and secondary PGE(2) release in isolated rat dura mater
Pain
Dural afferents express acid-sensing ion channels: a role for decreased meningeal pH in migraine headache
Pain
Measurement of the internal pH of mast cell granules using microvolumetric fluorescence and isotopic techniques
Arch Biochem Biophys
TRP channels and analgesia
Life Sci
AMPARs and synaptic plasticity: the last 25 years
Neuron
BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory?
Neurobiol Learn Mem
Chronic migraine—classification, characteristics and treatment
Nat Rev Neurol
Chronic migraine, classification, differential diagnosis, and epidemiology
Headache
Premonitory symptoms in migraine: an electronic diary study
Neurology
The premonitory phase of migraine and migraine management
Cephalalgia
Migraine and the neck
Headache
Pathophysiology of migraine
Ann Indian Acad Neurol
Migraine pain and nociceptor activation—where do we stand?
Headache
An analysis of migraine triggers in a clinic-based population
Headache
The triggers or precipitants of the acute migraine attack
Cephalalgia
Reduction in perceived stress as a migraine trigger: testing the “let-down headache” hypothesis
Neurology
Stress and migraine: something expected, something unexpected
Neurology
COX inhibitors for the treatment of migraine
Expert Opin Pharmacother
New drugs for migraine
J Headache Pain
Acute migraine therapy: new drugs and new approaches
Curr Treat Options Neurol
Taking the negative view of current migraine treatments
CNS Drugs
Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine
Headache
Medication-overuse headache: epidemiology, diagnosis and treatment
Ther Adv Drug Saf
Medication-overuse headache: a review
J Pain Res
Clopidogrel as prophylactic treatment for migraine: a pilot randomised, controlled study
Cephalalgia
Anatomy, physiology and surgical con-siderations of the spinal tract of the trigeminal nerve
J Neurophysiol
Detailed anatomy of the intracranial portion of the trigeminal nerve
J Neurosurg
Trigeminal nerve: anatomy and pathology
Br J Radiol
Referred pain
J N J Dent Assoc
Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists
Br J Pharmacol
Experimental studies on headache: pain-sensitive structures of the head and their significance in headache
Arch Surg
Cited by (37)
Brain targeting drug delivery systems for the management of brain disorders: molecular targets and nanotechnological strategies
2022, Multifunctional NanocarriersScreen of anti-migraine active compounds from Duijinsan by spectrum-effect relationship analysis and molecular docking
2021, Journal of EthnopharmacologyCitation Excerpt :TNF-α can up-regulate the expression of CGRP-mRNA in rat trigeminal nerve cells cultured in vitro through the JNK and P38 pathways of the MAPK signal transduction system, causing the release of CGRP. TNF-α also promotes the transcription of CGRP, stimulates the production of prostaglandin to produce hyperalgesia, activates meningeal nociceptors, improves neuronal excitability, and causes persistent headaches (Burgos-Vega et al., 2015). Studies have confirmed that the levels of IL, TNF-α and NF-κB in the plasma of migraine patients and migraine rats are significantly increased.
Review of aromatherapy essential oils and their mechanism of action against migraines
2021, Journal of EthnopharmacologyCitation Excerpt :The trigeminal neurovascular theory states that aseptic neurogenic inflammation is a key link to the pathogenesis of migraine. Following activation of the trigeminal neurovascular system in the dura mater, CGRP, SP, neurokinin A (NKA), and other vasoactive peptides are released, triggering the release of inflammatory cytokines, which results in sterile neurogenic inflammation that promotes migraine attacks (Burgos-Vega et al., 2015; Malhotra, 2016). In previous clinical studies, the levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) in patients with migraine were higher than those in healthy subjects (Martami et al., 2018; Yücel et al., 2016).
Are antimigraine drugs that influence CGRP levels justified?
2019, Pharmacological ReportsCitation Excerpt :In recent years, discussions on the pathophysiology of migraine are frequently directed to the role of the trigeminovascular system. During a migraine attack, nociceptors located in the dilated vessels of the meninges are stimulated, and this signal is transmitted by the trigeminal nerve to the trigeminal ganglion, then to the brainstem and sensory cortex [14,15]. The trigeminal nerve terminals release different neuropeptides, including calcitonin, CGRP, neurokinin A, and neuropeptide Y, which may lead to neurogenic inflammation.